JMP Securities Reiterates Market Outperform on Relay Therapeutics, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating for Relay Therapeutics (NASDAQ:RLAY) and maintained a price target of $21.
September 17, 2024 | 4:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated its Market Outperform rating for Relay Therapeutics, maintaining a price target of $21. This suggests confidence in the company's potential for growth.
The reiteration of a Market Outperform rating and maintenance of a $21 price target by JMP Securities indicates a positive outlook for Relay Therapeutics. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100